A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Clinical trial NCT00947167 · TERMINATED

Trial details

NCT number: NCT00947167
Sponsor: Pamela L. Kunz
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumors Carcinoid Tumors Adrenal Gland Tumors Neuroblastoma Pancreatic Neuroendocrine Tumors Multiple Endocrine Neoplasia

Start date: 2009-03-01
Primary completion: 2010-05-01
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.